A quaternary ammonium sulfonamide compound of formula (I): wherein R=(II), C.sub.1-C.sub.3 linear or branched alkyl, R.sub.1 and R.sub.2 are the same or different and selected from C.sub.1 to C.sub.18 linear or branched alkyl, R.sub.3 and R.sub.4 are the same or different and selected from C.sub.1 to C.sub.4 linear or branched alkyl, CF.sub.3, OR.sub.5 where R.sub.5 is C.sub.1 to C.sub.8 linear or branched alkyl or polyethylene oxide, l is 1, 2, 3, 4, 5, 6, 7 or 8, m is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17, n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18, wherein the aryl groups of R may be substituted or unsubstituted, X=halogen, and Y=(III) wherein R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are the same or different and selected from C.sub.1 to C.sub.6 linear or branched alkyl and the benzophenone is selected from the group consisting of substituted benzophenone and unsubstituted benzophenone, process for preparing the compound and antimicrobial surface coating compositions of the compound.

##STR00001##

A quaternary ammonium sulfonamide compound of formula (I): wherein R=(II), C.sub.1-C.sub.3 linear or branched alkyl, R.sub.1 and R.sub.2 are the same or different and selected from C.sub.1 to C.sub.18 linear or branched alkyl, R.sub.3 and R.sub.4 are the same or different and selected from C.sub.1 to C.sub.4 linear or branched alkyl, CF.sub.3, OR.sub.5 where R.sub.5 is C.sub.1 to C.sub.8 linear or branched alkyl or polyethylene oxide, l is 1, 2, 3, 4, 5, 6, 7 or 8, m is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17, n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18, wherein the aryl groups of R may be substituted or unsubstituted, X=halogen, and Y=(III) wherein R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are the same or different and selected from C.sub.1 to C.sub.6 linear or branched alkyl and the benzophenone is selected from the group consisting of substituted benzophenone and unsubstituted benzophenone, process for preparing the compound and antimicrobial surface coating compositions of the compound.

##STR00001##

The invention provides methods for treating pain using compounds having the general formula:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.A, subscript n, ring A, X.sup.2, L, subscript m, X.sup.1, ring D, R.sup.1, and R.sup.N have the meaning as described herein.

The invention provides methods for treating pain using compounds having the general formula:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.A, subscript n, ring A, X.sup.2, L, subscript m, X.sup.1, ring D, R.sup.1, and R.sup.N have the meaning as described herein.

Dimethylamine (Me.sub.2NH) is reacted with sulfuryl fluoride (SO.sub.2F.sub.2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FSO.sub.2NMe.sub.2), tetramethylsulfamide (SO.sub.2(NMe.sub.2).sub.2), or a combination thereof. A second phase, which may include dimethylamine hydrofluoride (Me.sub.2NH.sub.2F), may be also formed and separated from the first phase. FSO.sub.2NMe.sub.2 or SO.sub.2(NMe.sub.2).sub.2 is then isolated from the first phase. For example, the first phase may be a liquid phase, and FSO.sub.2NMe.sub.2 and SO.sub.2(NMe.sub.2).sub.2 are separated by distillation, optionally under reduced pressure.

Dimethylamine (Me.sub.2NH) is reacted with sulfuryl fluoride (SO.sub.2F.sub.2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FSO.sub.2NMe.sub.2), tetramethylsulfamide (SO.sub.2(NMe.sub.2).sub.2), or a combination thereof. A second phase, which may include dimethylamine hydrofluoride (Me.sub.2NH.sub.2F), may be also formed and separated from the first phase. FSO.sub.2NMe.sub.2 or SO.sub.2(NMe.sub.2).sub.2 is then isolated from the first phase. For example, the first phase may be a liquid phase, and FSO.sub.2NMe.sub.2 and SO.sub.2(NMe.sub.2).sub.2 are separated by distillation, optionally under reduced pressure.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

The present disclosure relates to a lipid compound of formula (Ia) or (AL-GI):

##STR00001##

having various cleavable linkers defined by the variables Z.sub.1 and Z.sub.2 and Z.sup.10 and Z.sup.20. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering an effector, e.g., a therapeutic agent.

The present disclosure relates to a lipid compound of formula (Ia) or (AL-GI):

##STR00001##

having various cleavable linkers defined by the variables Z.sub.1 and Z.sub.2 and Z.sup.10 and Z.sup.20. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering an effector, e.g., a therapeutic agent.